Free Trial
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Agios Pharmaceuticals logo
$36.21 +0.05 (+0.14%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$34.84 -1.38 (-3.80%)
As of 08/5/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Key Stats

Today's Range
$34.82
$36.80
50-Day Range
$30.83
$40.56
52-Week Range
$23.42
$62.58
Volume
1.17 million shs
Average Volume
1.09 million shs
Market Capitalization
$2.10 billion
P/E Ratio
3.29
Dividend Yield
N/A
Price Target
$56.33
Consensus Rating
Moderate Buy

Company Overview

Agios Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

AGIO MarketRank™: 

Agios Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 354th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Agios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Agios Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Agios Pharmaceuticals is 3.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.78.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Agios Pharmaceuticals is 3.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.91.

  • Price to Book Value per Share Ratio

    Agios Pharmaceuticals has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.55% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently increased by 10.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Agios Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Agios Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.55% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently increased by 10.58%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Agios Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Agios Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,619,654.00 in company stock.

  • Percentage Held by Insiders

    Only 4.93% of the stock of Agios Pharmaceuticals is held by insiders.

  • Read more about Agios Pharmaceuticals' insider trading history.
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
SFDA approves Agios Pharma’s Pyrukynd for thalassemia
Agios shares drop after report notes deaths of Pyrukynd patients
See More Headlines

AGIO Stock Analysis - Frequently Asked Questions

Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of the year. Since then, AGIO shares have increased by 10.2% and is now trading at $36.21.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, July, 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by $0.19. The biopharmaceutical company earned $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 3.49% and a net margin of 1,590.42%.
Read the conference call transcript
.

Agios Pharmaceuticals' top institutional investors include Bank of New York Mellon Corp (0.46%), Nordea Investment Management AB (0.39%), TD Asset Management Inc (0.29%) and Allianz Asset Management GmbH (0.24%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Sarah Gheuens, Cecilia Jones, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends
.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
7/31/2025
Today
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGIO
CIK
1439222
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

High Price Target
$65.00
Low Price Target
$51.00
Potential Upside/Downside
+55.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$11.00
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$673.72 million
Net Margins
1,590.42%
Pretax Margin
1,698.66%
Return on Equity
-3.49%
Return on Assets
-3.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.48
Quick Ratio
14.04

Sales & Book Value

Annual Sales
$36.50 million
Price / Sales
57.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$23.57 per share
Price / Book
1.54

Miscellaneous

Outstanding Shares
58,100,000
Free Float
55,238,000
Market Cap
$2.10 billion
Optionable
Optionable
Beta
0.80

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:AGIO) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners